ONCY receives Nasdaq minimum bid price deficiency notice, compliance window runs to January 19, 2027
A Nasdaq deficiency letter landed at Oncolytics Biotech Inc. on July 20, 2026, triggering a formal compliance clock for shares of the San Diego-based biotech. The Nasdaq Listing Qualifications Staff notified the…
A Nasdaq deficiency letter landed at Oncolytics Biotech Inc. on July 20, 2026, triggering a formal compliance clock for shares of the San Diego-based biotech. The Nasdaq Listing Qualifications Staff notified the company, which trades under the ticker ONCY on the Nasdaq Capital Market, that its common stock had closed below $1.00 per share for 30 consecutive business days, placing it outside the Minimum Bid Price Requirement defined in Nasdaq Listing Rule 5550(a)(2). The company now has until January 19, 2027 to return to compliance or face a delisting proceeding.
The listing stays active for now
The deficiency letter does not immediately remove ONCY from the Nasdaq Capital Market. Shares continue to trade under the same symbol while the company works through the 180-calendar-day window that Nasdaq Listing Rule 5810(c)(3)(A) grants. The path to closing the matter: the closing bid price must reach at least $1.00 per share and hold that level for a minimum of ten consecutive business days. Nasdaq retains discretion under Listing Rule 5810(c)(3)(H) to require a longer run before issuing written confirmation of compliance.
A conditional second window
If Oncolytics Biotech does not satisfy the Minimum Bid Price Requirement by January 19, 2027, it may be eligible for a second 180-calendar-day extension. That path carries conditions. The company would need to meet the applicable market value of publicly held shares requirement, satisfy all other initial listing standards for the Nasdaq Capital Market except the bid price rule, and notify Nasdaq of its intent to cure the deficiency during the first compliance period. Nasdaq makes the eligibility call. If the company does not qualify, or if Nasdaq concludes the deficiency cannot be resolved within the extended period, ONCY's stock becomes subject to delisting.
What to watch
The 8-K, signed by Chief Financial Officer Kirk Look and filed July 24, 2026, says Oncolytics Biotech plans to monitor the closing bid price and assess its available options for regaining compliance. No specific remedy is named in the filing. January 19, 2027 is the first hard deadline on the tape.